NASDAQ:BMRA

Biomerica Stock Forecast, Price & News

$5.59

+0.19 (+3.52 %)

(As of 10/29/2020 05:07 PM ET)

Add

Compare

Today's Range

$5.34

Now: $5.59▼

$5.62

50-Day Range

$5.41

MA: $6.82▼

$7.85

52-Week Range

$2.05

Now: $5.59▼

$23.39

Volume77,146 shs

Average Volume851,620 shs

Market Capitalization$65.70 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.83

Biomerica, Inc., a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy that is designed to allow physicians to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms; Helicobacter pylori products; and develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Biomerica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, Biomerica has a forecasted upside of 96.4% from its current price of $5.60.
Amount of Analyst Coverage
Biomerica has only been the subject of 1 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Biomerica has received 128 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Biomerica has received 130 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Biomerica has received 50.39% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Biomerica and other stocks. Vote “Outperform” if you believe BMRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Biomerica does not currently pay a dividend.
Dividend Growth
Biomerica does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biomerica insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,595.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 23.70% of the stock of Biomerica is held by insiders.
Percentage Held by Institutions
Only 10.69% of the stock of Biomerica is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Biomerica are expected to grow in the coming year, from ($0.20) to $0.43 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biomerica is -17.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biomerica is -17.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Biomerica has a P/B Ratio of 3.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.93 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Diagnostic substances

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:BMRA

Previous Symbol

CUSIPN/A

CIK73290

Webwww.biomerica.com

Phone949-645-2111

Employees65

Debt

Debt-to-Equity RatioN/A

Current Ratio7.28

Quick Ratio5.01

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$6.69 million

Price / Sales9.82

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.43 per share

Price / Book3.91

Profitability

EPS (Most Recent Fiscal Year)($0.23)

Net Income$-2,340,000.00

Net Margins-52.42%

Return on Equity-40.08%

Return on Assets-28.77%

Miscellaneous

Outstanding Shares11,753,000

Market Cap$65.70 million

Next Earnings Date1/20/2021 (Estimated)

OptionableNot Optionable

$5.59

+0.19 (+3.52 %)

(As of 10/29/2020 05:07 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive BMRA News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

Biomerica (NASDAQ:BMRA) Frequently Asked Questions

How has Biomerica's stock been impacted by COVID-19?

Biomerica's stock was trading at $2.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BMRA shares have increased by 92.8% and is now trading at $5.59.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Biomerica?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Biomerica.

When is Biomerica's next earnings date?

Biomerica is scheduled to release its next quarterly earnings announcement on Wednesday, January 20th 2021.
View our earnings forecast for Biomerica.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) released its earnings results on Thursday, October, 15th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.06. The firm earned $1.14 million during the quarter, compared to analysts' expectations of $1.09 million. Biomerica had a negative net margin of 52.42% and a negative return on equity of 40.08%.
View Biomerica's earnings history.

What price target have analysts set for BMRA?

1 equities research analysts have issued 12 month target prices for Biomerica's shares. Their forecasts range from $11.00 to $11.00. On average, they expect Biomerica's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 96.8% from the stock's current price.
View analysts' price targets for Biomerica.

Are investors shorting Biomerica?

Biomerica saw a decrease in short interest during the month of September. As of September 30th, there was short interest totaling 665,300 shares, a decrease of 17.5% from the September 15th total of 806,300 shares. Based on an average daily trading volume, of 532,300 shares, the short-interest ratio is presently 1.2 days. Currently, 7.4% of the company's stock are sold short.
View Biomerica's Short Interest.

Who are some of Biomerica's key competitors?

Some companies that are related to Biomerica include Riot Blockchain (RIOT), VolitionRx (VNRX), VolitionRx (VNRX), Nymox Pharmaceutical (NYMX), OncoCyte (OCX), OncoCyte (OCX), Navidea Biopharmaceuticals (NAVB), Navidea Biopharmaceuticals (NAVB), Trinity Biotech (TRIB), ImmuCell (ICCC), StageZero Life Sciences (GNWSF), Achieve Life Sciences (ACHV), StageZero Life Sciences (GNWSD), Arca Biopharma (ABIO) and Akers Biosciences (AKER).
View all competitors.

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), Ampio Pharmaceuticals (AMPE), Opko Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).

Who are Biomerica's key executives?

Biomerica's management team includes the following people:

Mr. Zackary S. Irani, Chairman & CEO (Age 54, Pay $136.61k)
Mr. Allen C. Barbieri, Exec. Vice-Chairman (Age 62, Pay $7.5k)
Ms. Janet Moore, Treasurer, Sec. & Director (Age 69, Pay $109.11k)
Mr. Steven Sloan, Chief Financial Officer (Age 50)

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

Who are Biomerica's major shareholders?

Biomerica's stock is owned by a number of institutional and retail investors. Top institutional investors include Emerald Advisers LLC (0.09%). Company insiders that own Biomerica stock include Catherine Coste and Mark A Sirgo.
View institutional ownership trends for Biomerica.

Which institutional investors are buying Biomerica stock?

BMRA stock was purchased by a variety of institutional investors in the last quarter, including Emerald Advisers LLC.
View insider buying and selling activity for Biomerica.

How do I buy shares of Biomerica?

Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $5.59.

How big of a company is Biomerica?

Biomerica has a market capitalization of $65.70 million and generates $6.69 million in revenue each year. The company earns $-2,340,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. Biomerica employs 65 workers across the globe.

What is Biomerica's official website?

The official website for Biomerica is www.biomerica.com.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at 949-645-2111.

This page was last updated on 10/29/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings